[
  {
    "ts": "2026-01-13T10:35:00+00:00",
    "headline": "2 No-Brainer Dividend Stocks to Buy Right Now",
    "summary": "More than 60 straight years of increasing dividends reflects a strong commitment behind these stocks.",
    "url": "https://www.fool.com/investing/2026/01/13/2-no-brainer-dividend-stocks-to-buy-right-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "eba55e6c-a20d-323e-b4bd-c2318986a4e3",
      "content": {
        "id": "eba55e6c-a20d-323e-b4bd-c2318986a4e3",
        "contentType": "STORY",
        "title": "2 No-Brainer Dividend Stocks to Buy Right Now",
        "description": "",
        "summary": "More than 60 straight years of increasing dividends reflects a strong commitment behind these stocks.",
        "pubDate": "2026-01-13T10:35:00Z",
        "displayTime": "2026-01-13T10:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/65034140917f9dd521f14ba5f8402e05",
          "originalWidth": 1199,
          "originalHeight": 800,
          "caption": "Someone studying charts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W1xX3xR_CmNeXjtqK..bCw--~B/aD04MDA7dz0xMTk5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/65034140917f9dd521f14ba5f8402e05.cf.webp",
              "width": 1199,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X7RjWMLdbu5S_sZfvLDC9w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/65034140917f9dd521f14ba5f8402e05.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/13/2-no-brainer-dividend-stocks-to-buy-right-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-no-brainer-dividend-stocks-103500831.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^VIX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T10:24:00+00:00",
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
      "content": {
        "id": "1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f",
        "contentType": "STORY",
        "title": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
        "description": "",
        "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
        "pubDate": "2026-01-13T10:24:00Z",
        "displayTime": "2026-01-13T10:24:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1d0e3ef9-8bce-3c03-92ed-9f3f6b25fa5f/abbvie-strikes-a-100-billion.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uprYtz96.huIUAIJcxlT7w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LhuGYFvbZhLBqQD88UWabQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/0a2845aa6b4185d51e8f8c6cc2b1e7a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T13:00:00+00:00",
    "headline": "Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and transl",
    "url": "https://finance.yahoo.com/news/johnson-johnson-elevates-leadership-depression-130000149.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "de8368b7-167b-3df3-867d-9d56ff333cd9",
      "content": {
        "id": "de8368b7-167b-3df3-867d-9d56ff333cd9",
        "contentType": "STORY",
        "title": "Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and transl",
        "pubDate": "2026-01-13T13:00:00Z",
        "displayTime": "2026-01-13T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GXCxbsFDDz3fFTI03HwuBw--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qhQKh0p3toIAfsx9SijYTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-elevates-leadership-depression-130000149.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-elevates-leadership-depression-130000149.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T14:45:47+00:00",
    "headline": "Here’s What Lifted Johnson & Johnson (JNJ) in Q4",
    "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]",
    "url": "https://finance.yahoo.com/news/lifted-johnson-johnson-jnj-q4-144547215.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9e53a7a8-7f29-379f-a89f-3616e4bb8570",
      "content": {
        "id": "9e53a7a8-7f29-379f-a89f-3616e4bb8570",
        "contentType": "STORY",
        "title": "Here’s What Lifted Johnson & Johnson (JNJ) in Q4",
        "description": "",
        "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]",
        "pubDate": "2026-01-13T14:45:47Z",
        "displayTime": "2026-01-13T14:45:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bef70c0cbbe531204698d1f5bf856093",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RL78I13Rg0P5xK2Pj7z1cQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bef70c0cbbe531204698d1f5bf856093.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MNPYtieVgnNbIAihNZylYw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bef70c0cbbe531204698d1f5bf856093.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lifted-johnson-johnson-jnj-q4-144547215.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lifted-johnson-johnson-jnj-q4-144547215.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T12:54:00+00:00",
    "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
    "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
    "url": "https://finance.yahoo.com/news/inside-pfizers-oncology-performance-ahead-125400114.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "75248d53-dea8-362e-8707-5f73901ab206",
      "content": {
        "id": "75248d53-dea8-362e-8707-5f73901ab206",
        "contentType": "STORY",
        "title": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
        "description": "",
        "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
        "pubDate": "2026-01-13T12:54:00Z",
        "displayTime": "2026-01-13T12:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtA490SSyXq.BB5XEEYFSg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BdQSUWaJAMCKg7gp75c9jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9883d206905e7516b2353476e213e60c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/inside-pfizers-oncology-performance-ahead-125400114.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/inside-pfizers-oncology-performance-ahead-125400114.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-13T12:48:00+00:00",
    "headline": "What's Powering J&J's MedTech Growth Ahead of Q4 Release?",
    "summary": "JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.",
    "url": "https://finance.yahoo.com/news/whats-powering-j-js-medtech-124800639.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "672da013-0bc7-3d9d-8474-95530d8344b4",
      "content": {
        "id": "672da013-0bc7-3d9d-8474-95530d8344b4",
        "contentType": "STORY",
        "title": "What's Powering J&J's MedTech Growth Ahead of Q4 Release?",
        "description": "",
        "summary": "JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.",
        "pubDate": "2026-01-13T12:48:00Z",
        "displayTime": "2026-01-13T12:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tugIemz.T.iquqxVIoxpHw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SHyaOdZAc4DXCya2O4.DtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/whats-powering-j-js-medtech-124800639.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/whats-powering-j-js-medtech-124800639.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "SYK"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]